---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000046"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2023-01-03T23:59:59+00:00"
generated_at: "2026-06-20T21:14:22.417703+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award

## Summary
- At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.
- Phase 2/3 pancreatic cancer trial expected FPI 2023; 55% long-term disease control in prior P001 study.
- BARDA awarded maximum EZ-BAA funding for OT-101 long COVID; observational trial starts 2023.
- Subsidiary Pet2DAO to launch PDAO token and distribute to shareholders/stakeholders in 2023.
- R&D costs reduced >95%, G&A >50% per latest 10Q; new CMO and CRO added.

## SEC filing metadata
- accession: 0001493152-23-000046
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2023-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315223000046/0001493152-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315223000046/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000046
- JSON: https://secwatch.observer/filing/0001493152-23-000046.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.